Biotech firm Curis Q2 revenue rises to $2.7 mln

Curis

05/08/2025 13:13

Overview

Curis Q2 revenue rises to $2.7 mln, beating analyst expectations

Net loss for Q2 narrows to $8.6 mln, exceeding analyst estimates

Adjusted EPS for Q2 beats expectations, reflecting improved financial performance

Outlook

Curis expects to begin enrollment for CLL study later this year

Company plans head-to-head trial against gilteritinib in AML

Curis anticipates data from AML triplet study in December

Company's cash runway extended into Q1 2026

Result Drivers

CLINICAL TRIAL PROGRESS - Curis cites ongoing enrollment in TakeAim Lymphoma study

EXPENSE REDUCTION - Lower research and development costs contributed to improved financial results

REVENUE INCREASE - Slight rise in royalty revenues from Genentech/Roche sales of Erivedge

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.75 mln
$2.64 mln (5 Analysts)
Q2 Net Income
Beat
-$8.59 mln
-$14.30 mln (5 Analysts)
Q2 Basic EPS
Beat
-$0.68
-$0.89 (4 Analysts)
Q2 Income From Operations
Beat
-$8.25 mln
-$14.20 mln (5 Analysts)

Press Release: ID:nPn7pxhswa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)